Predictors of Liver Dysfunction After Transhepatic Arterial Chemo-embolization in Hepatocellular Carcinoma Patients
Digestive Diseases and Sciences · 2023
DOI: 10.1007/s10620-023-07984-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2023. Verfasst von Kun-Lin Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi Universit…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Although transhepatic arterial chemo-embolization (TACE) is beneficial for the survival of intermediate stage hepatocellular carcinoma (HCC) patients, its cost is the damage of liver reserve. Liver dysfunction is one of factors associated with TACE refractory status and poor prognosis. The study aims to determine the prevalence and predictors of liver dysfunction in HCC patients after TACE.. METHODS: Using the ASUS EMR search 3.0 system, the patients with discharge codes "HCC (C22.0)" plus "TACE" were collected since 2016 till 2021 in Taipei Tzu Chi Hospital. Liver reserve was determined by modified albumin-bilirubin (mALBI) grade. The liver dysfunction was defined as mALBI grade migration within 1-3 months after TACE.. RESULTS: A total of 220 HCC patients with 314 TACE were found in 5-year duration. Those with TACE-experienced tumors, incomplete laboratory data for mALBI grade and incorrect diagnosis coding were excluded. 91 HCC patients (62 male; mean age 65.86 ± 11.61 year-old) were recruited for final analysis. 10 (11%) patients with baseline mALBI grade 3 were excluded. The percentage of mALBI grade migration was 27.2% (22/81) after TACE. Binary logistic regression discovered "up-to-seven out" and "up-to-eleven out" were associated with mALBI grade migration after TACE. CONCLUSION: In this retrospective study, liver dysfunction occurred in 27.2% of HCC patients after TACE. "Up-to-seven out" and "up-to-eleven out" were predictors for liver dysfunction after TACE, suggesting early switch to systemic therapy to reduce the risk of liver dysfunction for HCC patients with high tumor burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, Hualien, Taiwan, ROC.
- Department of Gastroenterology and Hepatology, Tung's Taichung Metro Harbor Hospital, Taichung City, Taiwan, ROC.
- Department of Medical Imaging, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, Hualien, Taiwan, ROC.
- Department of Gastroenterology and Hepatology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, Hualien, Taiwan, ROC. uld888@yahoo.com.tw.
Förderung
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Zitieren
APA
Cheng, K. L., Cheng, Y. M., Chan, C. Y., & Wang, C. C. (2023). Predictors of Liver Dysfunction After Transhepatic Arterial Chemo-embolization in Hepatocellular Carcinoma Patients. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-023-07984-4
Vancouver
Cheng KL, Cheng YM, Chan CY, Wang CC. Predictors of Liver Dysfunction After Transhepatic Arterial Chemo-embolization in Hepatocellular Carcinoma Patients. Digestive Diseases and Sciences. 2023. doi:10.1007/s10620-023-07984-4
BibTeX
@article{Cheng2023,
author = {Cheng, Kun-Lin and Cheng, Yu-Ming and Chan, Cheng-Yi and Wang, Chia-Chi},
title = {Predictors of Liver Dysfunction After Transhepatic Arterial Chemo-embolization in Hepatocellular Carcinoma Patients},
journal = {Digestive Diseases and Sciences},
year = {2023},
doi = {10.1007/s10620-023-07984-4}
}
EUVIMED